Hepatitis Monthly

Published by: Kowsar

Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B

Fatemeh Bakhshizadeh 1 , Soheila Hekmat 1 , * , Maryam Keshvari 2 , Seyed Moayed Alavian 3 , Ehsan Mostafavi 4 , Hossein Keivani 5 , Amin Doosti-Irani 6 , Fatemeh Motevalli 1 and Bita Behnava 3
Authors Information
1 Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, IR Iran
2 Blood Transfusion Research Center, High Institute for Research and Education in Transfusion Medicine, Tehran, IR Iran
3 Middle East Liver Diseases Center (MELD), Tehran, IR Iran
4 Epidemiology Department, Pasteur Institute of Iran, Tehran, IR Iran
5 Virology Department, School of Medicine, Iran University of Medical Sciences, Tehran, IR Iran
6 Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
Article information
  • Hepatitis Monthly: May 01, 2015, 15 (5); e25749
  • Published Online: May 23, 2015
  • Article Type: Research Article
  • Received: December 1, 2014
  • Revised: January 28, 2015
  • Accepted: April 14, 2015
  • DOI: 10.5812/hepatmon.15(5)2015.25749

To Cite: Bakhshizadeh F, Hekmat S, Keshvari M, Alavian S M, Mostafavi E, et al. Efficacy of Tenofovir Disoproxil Fumarate Therapy in Nucleoside-Analogue Naive Iranian Patients Treated for Chronic Hepatitis B, Hepat Mon. 2015 ; 15(5):e25749. doi: 10.5812/hepatmon.15(5)2015.25749.

Copyright © 2015, Kowsar Corp. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Heijtink RA, Kruining J, de Wilde GA, Balzarini J, de Clercq E, Schalm SW. Inhibitory effects of acyclic nucleoside phosphonates on human hepatitis B virus and duck hepatitis B virus infections in tissue culture. Antimicrob Agents Chemother. 1994; 38(9): 2180-2[PubMed]
  • 2. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med. 2008; 359(23): 2442-55[DOI][PubMed]
  • 3. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, et al. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011; 140(1): 132-43[DOI][PubMed]
  • 4. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet. 2013; 381(9865): 468-75[DOI][PubMed]
  • 5. Ward JW, Lok AS, Thomas DL, El-Serag HB, Kim WR. Report on a single-topic conference on "Chronic viral hepatitis--strategies to improve effectiveness of screening and treatment". Hepatology. 2012; 55(1): 307-15[DOI][PubMed]
  • 6. Huntzinger A. AASLD Updates Chronic Hepatitis B Recommendations. Am Fam Physician. 2009; 79(4): 338-43
  • 7. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
  • 8. Yuen MF, Yuan HJ, Wong DK, Yuen JC, Wong WM, Chan AO, et al. Prognostic determinants for chronic hepatitis B in Asians: therapeutic implications. Gut. 2005; 54(11): 1610-4[DOI][PubMed]
  • 9. Liu BM, Li T, Xu J, Li XG, Dong JP, Yan P, et al. Characterization of potential antiviral resistance mutations in hepatitis B virus reverse transcriptase sequences in treatment-naive Chinese patients. Antiviral Res. 2010; 85(3): 512-9[DOI][PubMed]
  • 10. Gordon SC, Krastev Z, Horban A, Petersen J, Sperl J, Dinh P, et al. Efficacy of tenofovir disoproxil fumarate at 240 weeks in patients with chronic hepatitis B with high baseline viral load. Hepatology. 2013; 58(2): 505-13[DOI][PubMed]
  • 11. Ridruejo E. Treatment of chronic hepatitis B in clinical practice with entecavir or tenofovir. World J Gastroenterol. 2014; 20(23): 7169-80[DOI][PubMed]
  • 12. Baran B, Soyer OM, Ormeci AC, Gokturk S, Evirgen S, Bozbey HU, et al. Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. Antimicrob Agents Chemother. 2013; 57(4): 1790-6[DOI][PubMed]
  • 13. Lin B, Ha NB, Liu A, Trinh HN, Nguyen HA, Nguyen KK, et al. Low incidence of hepatitis B e antigen seroconversion in patients treated with oral nucleos(t)ides in routine practice. J Gastroenterol Hepatol. 2013; 28(5): 855-60[DOI][PubMed]
  • 14. Kau A, Vermehren J, Sarrazin C. Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol. 2008; 49(4): 634-51[DOI][PubMed]
  • 15. Zeuzem S, Gane E, Liaw YF, Lim SG, DiBisceglie A, Buti M, et al. Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B. J Hepatol. 2009; 51(1): 11-20[DOI][PubMed]
  • 16. Werle-Lapostolle B, Bowden S, Locarnini S, Wursthorn K, Petersen J, Lau G, et al. Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy. Gastroenterology. 2004; 126(7): 1750-8[PubMed]
  • 17. Chan HL, Wong VW, Tse AM, Tse CH, Chim AM, Chan HY, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007; 5(12): 1462-8[DOI][PubMed]
  • 18. Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, et al. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. 2011; 106(10): 1766-73[DOI][PubMed]
  • 19. Lee JM, Ahn SH, Kim HS, Park H, Chang HY, Kim do Y, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011; 53(5): 1486-93[DOI][PubMed]
  • 20. Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J Infect Dis. 2011; 204(3): 415-8[DOI][PubMed]
  • 21. Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, et al. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010; 52(5): 1611-20[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments